patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_154109 | REC_0011301 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 14.6 | 73 | female | 3 | 8 | 5.7 | 7 | osimertinib 80 mg daily | 4.2 | false | MSS | 2026-03-15T05:35:59.688799+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_331024 | REC_0011302 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 9.1 | 72 | female | 2 | 19 | 4 | 3 | osimertinib 80 mg daily | 11.7 | true | MSS | 2026-03-15T05:35:59.689028+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467787 | REC_0011303 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 13.7 | 58 | female | 0 | 16 | 5.4 | 7 | pembrolizumab 200 mg q3w | 19.4 | true | MSS | 2026-03-15T05:35:59.689263+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_387923 | REC_0011304 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 14.2 | 66 | female | 1 | 1 | 4.6 | 3 | sotorasib 960 mg daily | 15.4 | true | MSS | 2026-03-15T05:35:59.689493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_486556 | REC_0011305 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 9.3 | 58 | female | 1 | 18 | 7.4 | 5 | alectinib 600 mg BID | 4 | false | MSS | 2026-03-15T05:35:59.689726+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_478940 | REC_0011306 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 17.2 | 80 | female | 2 | 13 | 4.1 | 6 | osimertinib 80 mg daily | 10 | true | MSS | 2026-03-15T05:35:59.689960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_297569 | REC_0011307 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 30 | 12.8 | 73 | male | 1 | 26 | 4.6 | 4 | pembrolizumab 200 mg q3w | 11.7 | false | MSS | 2026-03-15T05:35:59.690196+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_278801 | REC_0011308 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 24 | 12.2 | 65 | female | 1 | 18 | 7 | 0 | sotorasib 960 mg daily | 49.5 | false | MSS | 2026-03-15T05:35:59.690430+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671124 | REC_0011309 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 14.8 | 59 | female | 1 | 2 | 4.8 | 2 | entrectinib 600 mg daily | 21.8 | true | MSI-H | 2026-03-15T05:35:59.690663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_286252 | REC_0011310 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 9.8 | 55 | male | 1 | 12 | 5.8 | 8 | alectinib 600 mg BID | 7.3 | true | MSS | 2026-03-15T05:35:59.690895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829679 | REC_0011311 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 18 | 74 | female | 3 | 15 | 5.4 | 2 | osimertinib 80 mg daily | 11.6 | true | MSI-H | 2026-03-15T05:35:59.691174+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_655204 | REC_0011312 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 4.6 | 53 | female | 0 | 87 | 6.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 8.1 | true | MSS | 2026-03-15T05:35:59.691409+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_657496 | REC_0011313 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 11 | 9.4 | 62 | female | 1 | 20 | 6.1 | 0 | alectinib 600 mg BID | 22.2 | true | MSS | 2026-03-15T05:35:59.691642+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146473 | REC_0011314 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 12.4 | 75 | female | 2 | 25 | 5.5 | 6 | sotorasib 960 mg daily | 11 | false | MSI-H | 2026-03-15T05:35:59.691875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_799910 | REC_0011315 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 32 | 14.1 | 61 | male | 0 | 20 | 4.1 | 5 | pembrolizumab 200 mg q3w | 9.2 | false | MSI-H | 2026-03-15T05:35:59.692146+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_470393 | REC_0011316 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 14.2 | 74 | female | 2 | 22 | 8.8 | 6 | alectinib 600 mg BID | 12 | true | MSI-H | 2026-03-15T05:35:59.692398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_269404 | REC_0011317 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 8.6 | 59 | female | 1 | 20 | 5.9 | 3 | osimertinib 80 mg daily | 14.5 | true | MSS | 2026-03-15T05:35:59.692634+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572308 | REC_0011318 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 11.8 | 73 | female | 1 | 9 | 6.7 | 2 | entrectinib 600 mg daily | 16 | false | MSS | 2026-03-15T05:35:59.692870+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_355512 | REC_0011319 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 27 | 7.5 | 62 | male | 1 | 18 | 4.8 | 0 | osimertinib 80 mg daily | 17.9 | true | MSS | 2026-03-15T05:35:59.693105+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_595159 | REC_0011320 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 3.3 | 69 | female | 1 | 22 | 7.2 | 1 | pembrolizumab 200 mg q3w | 20.4 | false | MSS | 2026-03-15T05:35:59.693338+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_320765 | REC_0011321 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 13.9 | 73 | female | 2 | 30 | 5.8 | 3 | osimertinib 80 mg daily | 16.2 | false | MSS | 2026-03-15T05:35:59.693573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_362989 | REC_0011322 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 7.7 | 72 | female | 1 | 28 | 8.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.3 | false | MSS | 2026-03-15T05:35:59.693809+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545383 | REC_0011323 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 7.1 | 70 | female | 2 | 22 | 7.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 19.9 | true | MSS | 2026-03-15T05:35:59.694060+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_882394 | REC_0011324 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 21 | 3 | 71 | female | 1 | 22 | 4.3 | 1 | pembrolizumab 200 mg q3w | 29.7 | true | MSS | 2026-03-15T05:35:59.694420+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802649 | REC_0011325 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 12.3 | 60 | male | 0 | 19 | 6.1 | 6 | entrectinib 600 mg daily | 12.7 | false | MSS | 2026-03-15T05:35:59.694692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839101 | REC_0011326 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 16.6 | 74 | female | 2 | 13 | 5 | 6 | alectinib 600 mg BID | 12.4 | true | MSS | 2026-03-15T05:35:59.694948+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_810300 | REC_0011327 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 13.6 | 72 | female | 2 | 22 | 5.4 | 2 | entrectinib 600 mg daily | 13.6 | true | MSS | 2026-03-15T05:35:59.695226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511591 | REC_0011328 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 13.8 | 67 | female | 0 | 13 | 5.7 | 3 | pembrolizumab 200 mg q3w | 6.2 | false | MSS | 2026-03-15T05:35:59.695493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_742994 | REC_0011329 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 13.4 | 81 | female | 1 | 11 | 5 | 6 | entrectinib 600 mg daily | 5.9 | false | MSS | 2026-03-15T05:35:59.695746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_120780 | REC_0011330 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 2.4 | 62 | female | 0 | 39 | 5.9 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.6 | false | MSS | 2026-03-15T05:35:59.696003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_426870 | REC_0011331 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 9.8 | 70 | female | 1 | 16 | 5 | 2 | osimertinib 80 mg daily | 23.8 | true | MSS | 2026-03-15T05:35:59.696396+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634581 | REC_0011332 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 10.3 | 76 | female | 1 | 12 | 6.4 | 2 | osimertinib 80 mg daily | 13.2 | false | MSI-H | 2026-03-15T05:35:59.696660+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_259544 | REC_0011333 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 15.1 | 83 | female | 2 | 23 | 4.5 | 4 | osimertinib 80 mg daily | 8.5 | true | MSI-H | 2026-03-15T05:35:59.696910+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_943751 | REC_0011334 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 26 | 6.1 | 80 | female | 1 | 60 | 7.2 | 2 | pembrolizumab 200 mg q3w | 14.5 | false | MSS | 2026-03-15T05:35:59.697153+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_781362 | REC_0011335 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 14.1 | 74 | female | 2 | 10 | 5.6 | 2 | sotorasib 960 mg daily | 21 | false | MSI-H | 2026-03-15T05:35:59.697412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_570642 | REC_0011336 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 7.1 | 80 | female | 2 | 8 | 5.5 | 2 | entrectinib 600 mg daily | 26.9 | true | MSS | 2026-03-15T05:35:59.697657+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507741 | REC_0011337 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 14 | 56 | male | 1 | 11 | 5 | 6 | entrectinib 600 mg daily | 15 | false | MSS | 2026-03-15T05:35:59.698068+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_892342 | REC_0011338 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 3 | 76 | female | 1 | 13 | 4.7 | 5 | alectinib 600 mg BID | 10 | true | MSS | 2026-03-15T05:35:59.698338+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_579294 | REC_0011339 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 11.2 | 63 | male | 0 | 3 | 6.1 | 2 | alectinib 600 mg BID | 17 | true | MSI-H | 2026-03-15T05:35:59.698599+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461992 | REC_0011340 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 14.1 | 72 | male | 0 | 20 | 6.3 | 1 | osimertinib 80 mg daily | 15.3 | true | MSI-H | 2026-03-15T05:35:59.698867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_471557 | REC_0011341 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 12.5 | 73 | female | 3 | 15 | 4.5 | 1 | entrectinib 600 mg daily | 15.1 | false | MSI-H | 2026-03-15T05:35:59.699143+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457560 | REC_0011342 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 6.6 | 67 | female | 0 | 9 | 3 | 1 | entrectinib 600 mg daily | 20.4 | true | MSS | 2026-03-15T05:35:59.699403+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_631168 | REC_0011343 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 13.4 | 64 | female | 0 | 13 | 4 | 3 | entrectinib 600 mg daily | 23.7 | false | MSI-H | 2026-03-15T05:35:59.699654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_627266 | REC_0011344 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 9.2 | 71 | female | 1 | 58 | 6.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 14.5 | false | MSS | 2026-03-15T05:35:59.699911+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584133 | REC_0011345 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 30 | 10.8 | 65 | male | 1 | 20 | 4.2 | 2 | pembrolizumab 200 mg q3w | 9.6 | false | MSS | 2026-03-15T05:35:59.700210+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_102429 | REC_0011346 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 14.5 | 80 | male | 1 | 11 | 4.5 | 1 | sotorasib 960 mg daily | 15.9 | false | MSS | 2026-03-15T05:35:59.700471+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_666221 | REC_0011347 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 34 | 13.3 | 72 | female | 1 | 20 | 6.3 | 2 | osimertinib 80 mg daily | 16.5 | true | MSS | 2026-03-15T05:35:59.700719+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703815 | REC_0011348 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 12.1 | 54 | male | 0 | 24 | 5.4 | 7 | osimertinib 80 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:59.700959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218798 | REC_0011349 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 9.3 | 68 | female | 1 | 20 | 4.5 | 1 | osimertinib 80 mg daily | 15.1 | true | MSS | 2026-03-15T05:35:59.701203+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_512132 | REC_0011350 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.4 | 66 | female | 0 | 52 | 3.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.2 | false | MSS | 2026-03-15T05:35:59.701548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532826 | REC_0011351 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13.1 | 54 | female | 0 | 9 | 7.4 | 8 | entrectinib 600 mg daily | 16.1 | false | MSS | 2026-03-15T05:35:59.701802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_924368 | REC_0011352 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 8.7 | 55 | female | 1 | 4 | 5.5 | 6 | alectinib 600 mg BID | 16.4 | true | MSS | 2026-03-15T05:35:59.702044+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_804112 | REC_0011353 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 24 | 14.4 | 73 | female | 1 | 19 | 3.2 | 0 | osimertinib 80 mg daily | 38.7 | false | MSI-H | 2026-03-15T05:35:59.702296+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684415 | REC_0011354 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 7.7 | 64 | male | 0 | 13 | 5 | 5 | alectinib 600 mg BID | 13.3 | false | MSS | 2026-03-15T05:35:59.702543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197125 | REC_0011355 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 9.3 | 64 | male | 0 | 14 | 4.4 | 7 | osimertinib 80 mg daily | 15.9 | true | MSS | 2026-03-15T05:35:59.702795+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_299639 | REC_0011356 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 14 | 6.6 | 65 | male | 1 | 28 | 5.2 | 6 | pembrolizumab 200 mg q3w | 10.5 | true | MSS | 2026-03-15T05:35:59.703057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_492329 | REC_0011357 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 11.4 | 77 | male | 1 | 10 | 6.6 | 1 | alectinib 600 mg BID | 24.3 | false | MSS | 2026-03-15T05:35:59.703309+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322959 | REC_0011358 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 13.7 | 67 | female | 0 | 15 | 4.9 | 1 | osimertinib 80 mg daily | 23.8 | false | MSI-H | 2026-03-15T05:35:59.703548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_428391 | REC_0011359 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 16.2 | 62 | male | 0 | 14 | 5.4 | 7 | pembrolizumab 200 mg q3w | 15.5 | true | MSS | 2026-03-15T05:35:59.703789+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_270522 | REC_0011360 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 16.1 | 70 | male | 2 | 8 | 8.7 | 5 | osimertinib 80 mg daily | 9.2 | true | MSS | 2026-03-15T05:35:59.704031+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_727112 | REC_0011361 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 19 | 3.1 | 72 | female | 1 | 26 | 4.7 | 2 | pembrolizumab 200 mg q3w | 13.9 | false | MSS | 2026-03-15T05:35:59.704502+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855686 | REC_0011362 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 11.9 | 59 | female | 1 | 16 | 3.7 | 2 | entrectinib 600 mg daily | 13.9 | false | MSI-H | 2026-03-15T05:35:59.704775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572118 | REC_0011363 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 39 | 15.1 | 83 | male | 0 | 23 | 6.2 | 5 | entrectinib 600 mg daily | 14.3 | false | MSS | 2026-03-15T05:35:59.705146+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136595 | REC_0011364 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 14.9 | 72 | female | 1 | 12 | 4.3 | 2 | alectinib 600 mg BID | 27 | true | MSI-H | 2026-03-15T05:35:59.705402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_962385 | REC_0011365 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 31 | 3.1 | 70 | female | 0 | 79 | 7.4 | 0 | carboplatin + paclitaxel + pembrolizumab | 36.5 | true | MSS | 2026-03-15T05:35:59.705642+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_551429 | REC_0011366 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 9.9 | 64 | male | 0 | 23 | 7.3 | 6 | alectinib 600 mg BID | 9.5 | true | MSS | 2026-03-15T05:35:59.705890+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_908087 | REC_0011367 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6 | 73 | male | 2 | 28 | 6.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 12 | true | MSS | 2026-03-15T05:35:59.706137+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_211973 | REC_0011368 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 10.8 | 70 | female | 1 | 21 | 4.8 | 2 | pembrolizumab 200 mg q3w | 26.4 | true | MSI-H | 2026-03-15T05:35:59.706373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_945831 | REC_0011369 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 10.1 | 67 | female | 0 | 16 | 4.6 | 6 | alectinib 600 mg BID | 7.9 | true | MSS | 2026-03-15T05:35:59.706614+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458980 | REC_0011370 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 11.8 | 67 | female | 1 | 23 | 7.7 | 5 | pembrolizumab 200 mg q3w | 4.9 | false | MSS | 2026-03-15T05:35:59.706859+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_166270 | REC_0011371 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 4 | 61 | female | 0 | 25 | 4.5 | 4 | pembrolizumab 200 mg q3w | 20.5 | true | MSS | 2026-03-15T05:35:59.707113+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763546 | REC_0011372 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 14.4 | 65 | male | 0 | 21 | 4.7 | 5 | entrectinib 600 mg daily | 8.4 | false | MSI-H | 2026-03-15T05:35:59.707371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831728 | REC_0011373 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 3.9 | 64 | male | 1 | 5 | 6.4 | 6 | entrectinib 600 mg daily | 12.1 | true | MSS | 2026-03-15T05:35:59.707626+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_200853 | REC_0011374 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 12.8 | 55 | female | 0 | 0 | 5.8 | 4 | osimertinib 80 mg daily | 12.7 | false | MSI-H | 2026-03-15T05:35:59.707889+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_740965 | REC_0011375 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13.6 | 78 | female | 1 | 11 | 5.4 | 6 | entrectinib 600 mg daily | 14.8 | false | MSI-H | 2026-03-15T05:35:59.708234+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_178747 | REC_0011376 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 8.7 | 78 | female | 1 | 30 | 5.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.3 | true | MSS | 2026-03-15T05:35:59.708618+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_728761 | REC_0011377 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 7.4 | 81 | female | 1 | 22 | 6.4 | 7 | pembrolizumab 200 mg q3w | 6.8 | false | MSS | 2026-03-15T05:35:59.708878+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454330 | REC_0011378 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 10.2 | 57 | female | 0 | 17 | 6.7 | 6 | alectinib 600 mg BID | 10.4 | false | MSI-H | 2026-03-15T05:35:59.709154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322792 | REC_0011379 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 7.6 | 81 | female | 1 | 14 | 5.4 | 6 | alectinib 600 mg BID | 9.1 | true | MSS | 2026-03-15T05:35:59.709426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_774583 | REC_0011380 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 7.4 | 82 | female | 2 | 13 | 3.6 | 7 | pembrolizumab 200 mg q3w | 8 | false | MSS | 2026-03-15T05:35:59.709715+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153974 | REC_0011381 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 11.5 | 74 | female | 1 | 2 | 5.5 | 2 | osimertinib 80 mg daily | 18.1 | false | MSI-H | 2026-03-15T05:35:59.710017+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_568069 | REC_0011382 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 6.5 | 63 | male | 1 | 21 | 5.6 | 4 | osimertinib 80 mg daily | 4.5 | true | MSS | 2026-03-15T05:35:59.710298+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467097 | REC_0011383 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 10.2 | 68 | female | 1 | 15 | 7.5 | 5 | sotorasib 960 mg daily | 14.7 | false | MSS | 2026-03-15T05:35:59.710586+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_737881 | REC_0011384 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 9.5 | 81 | female | 2 | 10 | 4.4 | 7 | osimertinib 80 mg daily | 16.1 | false | MSS | 2026-03-15T05:35:59.710869+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_568081 | REC_0011385 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 8.4 | 73 | female | 2 | 23 | 6.2 | 2 | sotorasib 960 mg daily | 22.9 | false | MSS | 2026-03-15T05:35:59.711155+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_424971 | REC_0011386 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 9.2 | 67 | male | 0 | 32 | 4.2 | 6 | osimertinib 80 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:59.711441+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257759 | REC_0011387 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 7 | 81 | female | 1 | 14 | 6.2 | 3 | pembrolizumab 200 mg q3w | 10.5 | false | MSS | 2026-03-15T05:35:59.711699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_204067 | REC_0011388 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 15 | 16.1 | 63 | male | 1 | 19 | 4.8 | 2 | sotorasib 960 mg daily | 9.9 | true | MSI-H | 2026-03-15T05:35:59.711952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639564 | REC_0011389 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 30 | 5.4 | 84 | female | 1 | 40 | 4.1 | 3 | pembrolizumab 200 mg q3w | 18.2 | false | MSS | 2026-03-15T05:35:59.712405+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_745050 | REC_0011390 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 14.1 | 77 | female | 3 | 15 | 6.8 | 2 | osimertinib 80 mg daily | 14.7 | false | MSS | 2026-03-15T05:35:59.712687+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826852 | REC_0011391 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 4.4 | 75 | female | 1 | 15 | 7.9 | 2 | pembrolizumab 200 mg q3w | 19.6 | true | MSS | 2026-03-15T05:35:59.712929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271377 | REC_0011392 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 15.9 | 58 | female | 1 | 26 | 5.9 | 1 | osimertinib 80 mg daily | 17.8 | false | MSS | 2026-03-15T05:35:59.713177+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293246 | REC_0011393 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 6.9 | 76 | female | 2 | 24 | 4.6 | 3 | pembrolizumab 200 mg q3w | 11.7 | false | MSS | 2026-03-15T05:35:59.713412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_276610 | REC_0011394 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 13 | 75 | female | 1 | 12 | 6.8 | 1 | sotorasib 960 mg daily | 24.4 | false | MSI-H | 2026-03-15T05:35:59.713649+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_550305 | REC_0011395 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 5.1 | 61 | male | 1 | 9 | 5.3 | 6 | osimertinib 80 mg daily | 6.6 | true | MSS | 2026-03-15T05:35:59.713888+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467284 | REC_0011396 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 14 | 16.4 | 75 | female | 1 | 17 | 5.6 | 9 | sotorasib 960 mg daily | 7.4 | false | MSS | 2026-03-15T05:35:59.714127+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_619180 | REC_0011397 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 5.6 | 81 | female | 0 | 24 | 4.7 | 5 | entrectinib 600 mg daily | 17.4 | false | MSS | 2026-03-15T05:35:59.714362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_134169 | REC_0011398 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 27 | 2.2 | 68 | female | 1 | 16 | 5.8 | 1 | pembrolizumab 200 mg q3w | 15 | false | MSS | 2026-03-15T05:35:59.714598+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304908 | REC_0011399 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 15.5 | 70 | female | 2 | 3 | 6.9 | 1 | entrectinib 600 mg daily | 19.4 | true | MSS | 2026-03-15T05:35:59.714838+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_512260 | REC_0011400 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 15 | 16 | 66 | female | 1 | 14 | 3.8 | 7 | entrectinib 600 mg daily | 9.4 | false | MSI-H | 2026-03-15T05:35:59.715081+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.